Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19006997 | CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE | December 2024 | July 2025 | Allow | 6 | 1 | 0 | No | No |
| 18942121 | TNF-ALPHA VARIANT FUSION MOLECULES | November 2024 | July 2025 | Allow | 8 | 1 | 1 | No | No |
| 18651002 | NOTCH4 ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATING AIRWAY INFLAMMATION | April 2024 | December 2024 | Allow | 8 | 1 | 0 | No | No |
| 18619759 | TNFR2 Agonists with Improved Stability | March 2024 | September 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18695013 | COLLAGEN HYDROLYSATE FOR USE IN PREVENTION AND/OR TREATMENT OF POST INTENSIVE CARE SYNDROME (PICS) | March 2024 | December 2024 | Allow | 9 | 0 | 1 | Yes | No |
| 18587502 | BISPECIFIC ANTIBODY THAT BINDS TO CD116 AND CD131 | February 2024 | August 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18496397 | Serum Albumin-Binding Fibronectin Type III Domains | October 2023 | January 2026 | Allow | 27 | 1 | 0 | No | No |
| 18474781 | TREATMENTS ADMINISTERING CHIMERIC IGG FC RECEPTOR COMPRISING AN EXTRACELLULAR DOMAIN OF CD64 | September 2023 | December 2025 | Allow | 26 | 1 | 1 | No | No |
| 18470745 | CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE | September 2023 | October 2025 | Allow | 24 | 1 | 0 | Yes | No |
| 18458692 | CD47 BLOCKADE THERAPY WITH CD38 ANTIBODY | August 2023 | January 2026 | Abandon | 28 | 1 | 0 | Yes | No |
| 18337875 | HUMANIZED ANTIBODY SPECIFIC FOR CD22 AND CHIMERIC ANTIGEN RECEPTOR USING THE SAME | June 2023 | March 2025 | Allow | 21 | 0 | 0 | No | No |
| 18327456 | MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT | June 2023 | October 2025 | Allow | 28 | 1 | 0 | No | No |
| 18321249 | Anti-Jagged Antibodies and Methods of Use | May 2023 | May 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18195184 | METHODS FOR TREATING DRUG RESISTANT CANCERS | May 2023 | January 2026 | Allow | 32 | 1 | 1 | No | No |
| 18312045 | INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF | May 2023 | May 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18296510 | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION | April 2023 | May 2025 | Allow | 25 | 1 | 0 | No | No |
| 18295631 | EXOSOME FOR STIMULATING T CELL AND PHARMACEUTICAL USE THEREOF | April 2023 | October 2024 | Allow | 18 | 0 | 0 | No | No |
| 18191712 | NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES | March 2023 | January 2026 | Abandon | 34 | 2 | 1 | No | No |
| 18185443 | VEGFR Fusion Protein Pharmaceutical Composition | March 2023 | February 2025 | Allow | 23 | 1 | 0 | No | No |
| 18121468 | Hematopoietic Stem Cell Engraftment | March 2023 | February 2026 | Allow | 35 | 1 | 0 | No | No |
| 18183804 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | March 2023 | April 2025 | Allow | 25 | 1 | 1 | No | No |
| 18182829 | HUMAN OTIC PROGENITOR IDENTIFICATION AND ISOLATION | March 2023 | September 2024 | Allow | 18 | 1 | 0 | No | No |
| 18025398 | HIGH-ACTIVITY BLOOD COAGULATION FACTOR XI MUTANT ALA570THR | March 2023 | February 2026 | Allow | 36 | 1 | 0 | No | No |
| 18041845 | A FUSION PROTEIN COMPRISING AN ANTIGEN BINDING DOMAIN AND A CYTOKINE TRIMER DOMAIN | February 2023 | June 2024 | Allow | 16 | 1 | 0 | No | No |
| 18167265 | AMELIORATION AND TREATMENT OF INFARCTION DAMAGE | February 2023 | March 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18107386 | PREFILLED SYRINGE WITH PEGFILGRASTIM HAVING OPTIMIZED DOSE AND METHODS RELATED THERETO | February 2023 | February 2025 | Allow | 25 | 1 | 1 | No | No |
| 18006370 | IL27RAlpha Binding Molecules and Methods of Use | January 2023 | July 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 18014288 | Extracellular Vesicles and Compositions Thereof | January 2023 | March 2026 | Allow | 38 | 1 | 0 | No | No |
| 18069704 | ANTIBODY CONSTRUCTS FOR DLL3 AND CD3 | December 2022 | July 2025 | Allow | 31 | 1 | 1 | No | No |
| 18061066 | METHODS RELATED TO THE TREATMENT OF IGA NEPHROPATHY | December 2022 | January 2026 | Allow | 37 | 1 | 0 | Yes | No |
| 17992529 | Blood Biomarkers and Diagnostic Methods for Small Vessel Diseases | November 2022 | August 2024 | Allow | 21 | 1 | 0 | No | No |
| 17924427 | INHIBITION OF SARS-COV-2 INFECTION THROUGH SYNDECANS | November 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18047039 | ANTI-HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODY AND PREPARATION METHOD AND APPLICATION THEREOF | October 2022 | November 2023 | Allow | 13 | 1 | 0 | No | No |
| 17934064 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | September 2022 | December 2024 | Allow | 27 | 0 | 1 | Yes | No |
| 17933229 | NOVEL ANTI-PAD4 ANTIBODY | September 2022 | June 2025 | Allow | 33 | 1 | 0 | No | No |
| 17931049 | OPTIMIZED ANTI-TL1A ANTIBODIES | September 2022 | October 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17798481 | METHODS OF USE OF SOLUBLE CD24 FOR TREATING SARS-COV-2 INFECTION | August 2022 | January 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17816823 | IL-2 SUPERAGONISTS IN COMBINATION WITH ANTI-PD-1 ANTIBODIES | August 2022 | February 2025 | Allow | 31 | 2 | 0 | No | No |
| 17796307 | METHODS OF USE OF SOLUBLE CD24 FOR TREATING VIRAL PNEUMONIA | July 2022 | December 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17792608 | METHOD OF PRODUCING ADM COLLAGEN FIBER, ADM COLLAGEN FIBER PRODUCED USING METHOD, AND APPARATUS FOR PRODUCING ADM COLLAGEN FIBER | July 2022 | February 2026 | Allow | 43 | 1 | 1 | No | No |
| 17846950 | TREATMENT FOR PRIMARY AMYLOIDOSIS WITH ANTI-BCMA BINDING PROTEIN | June 2022 | October 2024 | Allow | 28 | 1 | 0 | No | No |
| 17841704 | METHODS OF PROGNOSIS AND TREATMENT | June 2022 | October 2024 | Allow | 28 | 1 | 1 | No | No |
| 17841595 | PROTEOLYTICALLY CLEAVABLE CHIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | June 2022 | March 2025 | Allow | 33 | 2 | 0 | No | No |
| 17832654 | METHODS OF RISK ASSESSMENT AND DISEASE CLASSIFICATION | June 2022 | November 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17663260 | VEGFR Fusion Protein Pharmaceutical Composition | May 2022 | March 2023 | Allow | 10 | 2 | 0 | No | No |
| 17738620 | Interleukin-4 Receptor-Binding Fusion Proteins and Uses Thereof | May 2022 | July 2025 | Allow | 39 | 1 | 0 | No | No |
| 17733640 | COMPOSITIONS AND METHODS FOR ENHANCING INNATE IMMUNITY IN A SUBJECT FOR TREATMENT OF INFECTIONS AND CANCER AND OTHER ACUTE AND CHRONIC CONDITIONS OF THE EYE | April 2022 | August 2025 | Allow | 40 | 2 | 0 | No | No |
| 17731976 | NUCLEIC ACID CONSTRUCT THAT ENCODES CHIMERIC RHODOPSIN | April 2022 | May 2023 | Allow | 13 | 1 | 1 | No | No |
| 17732420 | CD137 BINDING FIBRONECTIN TYPE III DOMAINS | April 2022 | November 2024 | Allow | 31 | 2 | 1 | No | No |
| 17717200 | EARLY DIAGNOSIS OF INFECTIONS | April 2022 | March 2024 | Allow | 23 | 1 | 0 | No | No |
| 17767606 | Anti-Chemokine Like Receptor 1 Humanized Antibodies and Their Therapeutic Applications | April 2022 | September 2025 | Allow | 42 | 1 | 0 | No | No |
| 17716630 | METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS | April 2022 | January 2025 | Allow | 33 | 2 | 1 | No | No |
| 17716636 | METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS | April 2022 | December 2025 | Allow | 44 | 4 | 1 | Yes | No |
| 17710559 | Hemostatic Textile | March 2022 | December 2025 | Allow | 44 | 1 | 0 | Yes | No |
| 17701372 | SIGNATURE OF TL1A (TNFSF15) SIGNALING PATHWAY | March 2022 | December 2024 | Allow | 32 | 2 | 1 | No | No |
| 17697070 | S-LAYER PROTEIN 2D LATTICE COUPLED DETERGENT-FREE GPCR BIOELECTRONIC INTERFACES, DEVICES, AND METHODS FOR USE THEREOF | March 2022 | November 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17695769 | CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN | March 2022 | September 2023 | Allow | 18 | 0 | 0 | No | No |
| 17642923 | NUCLEIC ACID CONSTRUCT THAT ENCODES CHIMERIC RHODOPSIN | March 2022 | December 2025 | Allow | 45 | 2 | 0 | No | No |
| 17694541 | COMPOSITIONS AND METHODS FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS | March 2022 | September 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17686453 | MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT | March 2022 | June 2024 | Allow | 27 | 1 | 1 | No | No |
| 17686536 | ANTI-IL-31RA ANTIBODY-CONTAINING FORMULATIONS | March 2022 | August 2024 | Allow | 29 | 1 | 0 | No | No |
| 17682922 | HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | February 2022 | March 2024 | Allow | 25 | 1 | 1 | No | No |
| 17680719 | MEDICINE FOR TREATING CANCER BY ADMINISTERING A TOLL-LIKE RECEPTOR AGONIST AND LAG-3 IgG FUSION PROTEIN | February 2022 | May 2023 | Allow | 14 | 0 | 0 | No | No |
| 17672889 | ANTI-JAGGED1 ANTIGEN BINDING PROTEINS | February 2022 | September 2023 | Allow | 19 | 1 | 0 | No | No |
| 17634120 | NOVEL COMPOSITION COMPRISING ANTIBODIES | February 2022 | December 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17665909 | ANTI-CD40 ANTIBODIES | February 2022 | January 2026 | Abandon | 47 | 1 | 0 | No | No |
| 17573991 | METHODS OF ADMINISTERING ANTI-IL31A ANTIBODY-CONTAINING FORMULATIONS | January 2022 | March 2023 | Allow | 14 | 0 | 0 | Yes | No |
| 17569261 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | January 2022 | September 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17563846 | HUMANIZED ANTIBODY SPECIFIC FOR CD22 AND CHIMERIC ANTIGEN RECEPTOR USING THE SAME | December 2021 | November 2024 | Allow | 35 | 2 | 0 | Yes | No |
| 17561606 | COMPOSITIONS COMPRISING ALBUMIN-FMS-LIKE TYROSINE KINASE 3 LIGAND FUSION PROTEINS AND USES THEREOF | December 2021 | March 2025 | Allow | 39 | 2 | 0 | Yes | Yes |
| 17557654 | PROTEASE-ACTIVATING CD45-GATE CAR | December 2021 | April 2025 | Allow | 40 | 1 | 1 | No | No |
| 17555357 | T Cell Modulator | December 2021 | October 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17552841 | A METHOD FOR TREATING DISEASE USING FOXP3+CD4+ T CELLS | December 2021 | June 2022 | Allow | 6 | 3 | 0 | Yes | No |
| 17616497 | USE OF CD9 AS A BIOMARKER AND AS A BIOTARGET IN GLOMERULONEPHRITIS OR GLOMERULOSCLEROSIS | December 2021 | September 2025 | Allow | 46 | 1 | 1 | No | No |
| 17540947 | ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS | December 2021 | January 2024 | Allow | 26 | 1 | 1 | No | No |
| 17526883 | ANTI-TLR4 ANTIBODIES AND USES THEREOF | November 2021 | October 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17450282 | ANTI-NOTCH3 ANTIBODY | October 2021 | February 2025 | Allow | 40 | 4 | 0 | No | No |
| 17493938 | PROTEIN-BASED PURIFICATION MATRICES AND METHODS OF USING THE SAME | October 2021 | November 2022 | Allow | 13 | 3 | 0 | Yes | No |
| 17489391 | FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY | September 2021 | June 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17441708 | ANTI-EGFRVIII ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF | September 2021 | October 2025 | Allow | 49 | 2 | 0 | No | No |
| 17472004 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS | September 2021 | September 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17435325 | ENGINEERED CD47 EXTRACELLULAR DOMAIN FOR BIOCONJUGATION | August 2021 | February 2026 | Allow | 53 | 1 | 1 | No | No |
| 17397447 | Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Colorectal Cancer | August 2021 | July 2024 | Allow | 36 | 2 | 1 | No | No |
| 17397287 | INTERLEUKIN-4 RECEPTOR-BINDING FUSION PROTEINS AND USES THEREOF | August 2021 | January 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17396792 | METHODS AND REAGENTS FOR MODULATING MACROPHAGE PHENOTYPE | August 2021 | February 2024 | Allow | 30 | 1 | 0 | No | No |
| 17396351 | Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist | August 2021 | June 2024 | Allow | 34 | 1 | 1 | No | No |
| 17429093 | A METHOD FOR THE TREATMENT OR PROPHYLAXIS OF CANCER BY TARGETING THE EXTRACELLULAR PORTION OF KERATIN 14 (KRT14) RESIDING ON CANCER CELLS | August 2021 | March 2026 | Allow | 55 | 2 | 1 | No | No |
| 17427581 | HALF-LIFE EXTENDED IMMTAC BINDING CD3 AND A HLA-A*02 RESTRICTED PEPTIDE | July 2021 | June 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17423999 | ANTI-ELASTIN ANTIBODIES AND METHODS OF USE | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17376233 | ANTI-IL-36R ANTIBODIES FOR THE TREATMENT OF PYODERMA GANGRENOSUM | July 2021 | August 2024 | Allow | 37 | 1 | 1 | No | No |
| 17377297 | NUCLEIC ACID FOR TREATING MITE ALLERGY | July 2021 | December 2021 | Allow | 5 | 1 | 0 | Yes | No |
| 17372575 | PROTEIN SIGNATURES FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS | July 2021 | March 2024 | Allow | 32 | 1 | 0 | No | No |
| 17415348 | Combination Treatments Of Cancer Comprising A TLR Agonist | June 2021 | February 2026 | Abandon | 56 | 2 | 1 | No | No |
| 17346421 | ANTI-IL31RA ANTIBODY-CONTAINING FORMULATIONS | June 2021 | November 2021 | Allow | 5 | 0 | 0 | No | No |
| 17413045 | ANTI-HUMAN INTERLEUKIN 5(IL-5) MONOCLONAL ANTIBODY AND USE THEREOF | June 2021 | April 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17312590 | IMMUNOHISTOCHEMICAL STAINING FOR GSK-3 | June 2021 | September 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17299239 | REGULATABLE CELL SURFACE RECEPTORS AND RELATED COMPOSITIONS AND METHODS | June 2021 | June 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17330716 | COMBINATION THERAPY FOR TREATMENT OF DISEASE | May 2021 | December 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17320128 | ANTI-JAGGED1 ANTIGEN BINDING PROTEINS | May 2021 | September 2023 | Allow | 29 | 1 | 1 | No | No |
| 17317789 | Methods for Treating Multiple Myeloma | May 2021 | November 2023 | Allow | 30 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BUNNER, BRIDGET E.
With a 36.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BUNNER, BRIDGET E works in Art Unit 1647 and has examined 1,142 patent applications in our dataset. With an allowance rate of 53.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner BUNNER, BRIDGET E's allowance rate of 53.8% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BUNNER, BRIDGET E receive 1.56 office actions before reaching final disposition. This places the examiner in the 29% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by BUNNER, BRIDGET E is 33 months. This places the examiner in the 46% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +30.2% benefit to allowance rate for applications examined by BUNNER, BRIDGET E. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 28.0% of applications are subsequently allowed. This success rate is in the 50% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 52.9% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 78.4% of appeals filed. This is in the 70% percentile among all examiners. Of these withdrawals, 80.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 74.4% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 8.4% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.2% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.